Spravato Patient Reviews: Dissociation, Cost, and Relief

Patients prescribed Spravato (esketamine nasal spray) report high satisfaction overall, with one structured study finding that every participant described themselves as either satisfied or very satisfied with treatment. But behind that headline number is a complex treatment experience that varies widely from person to person, involving dissociative side effects, mandatory clinic monitoring sessions, insurance obstacles, and the open question of how long gains last. What patients actually go through during and between dosing sessions fills in a picture that clinical trial summaries alone cannot capture.

What Patient Satisfaction Studies Actually Show

The most detailed look at how patients themselves evaluate Spravato comes from the STRIVE study, which specifically asked people with treatment-resistant depression to describe their experience in their own words. Roughly 92% of participants said the treatment had improved or much improved the effects of depression on their health. When asked about what stood out, patients most commonly mentioned how well it worked, how quickly it worked, and its side-effect profile. All 170 patients surveyed reported being satisfied or very satisfied.¹

A separate physician-and-patient survey in the United States found that roughly two-thirds to three-quarters of patients showed clinical improvement after starting esketamine, and patients reported favorable outcomes in their activities of daily living as well.² These numbers are encouraging, but they come with an important caveat: the patients surveyed had already continued with treatment long enough to be surveyed, which means people who dropped out early due to side effects or lack of benefit are underrepresented.

How Quickly the Relief Arrives

Speed of onset is one of the features patients talk about most. Traditional oral antidepressants can take four to six weeks to produce meaningful improvement. Spravato works on a different timeline. Clinical trials, including the TRANSFORM-2, SUSTAIN-1, and ASPIRE studies, showed that esketamine produces antidepressant effects within hours of the first dose.³

A real-world observational program at the Institute of Living in Hartford, Connecticut, tracked patients over sixteen weeks and found that people who started with moderate-to-severe depressive symptoms dropped into the mild range after about four weeks, and that improvement held steady through the full study period.⁴ For people who have tried multiple antidepressants without success, noticing a shift within days rather than weeks can feel transformative. That said, the rapid onset is not universal, and some patients need several sessions before they notice a clear change.

What Dissociation Feels Like During Treatment

Dissociation is the side effect that dominates patient conversations about Spravato. It can include a feeling of detachment from your body or surroundings, perceptual distortions, confusion, or a dream-like state. In a pooled analysis of first-dose data from over 760 patients, investigators reported dissociative side effects in about 14% of cases. Most were mild, some were moderate, and fewer than 1% were severe. The symptoms generally resolved within an hour and a half of dosing.⁵

What those numbers do not capture is the range of subjective experiences. One published case report followed a patient who experienced agitation and confusion starting about twenty minutes after dosing, lasting roughly forty minutes. The patient found that listening to music of her own choosing noticeably reduced the unpleasantness of the dissociation within about five minutes, making the experience tolerable where it had previously been distressing.⁶ This simple coping strategy is something many patients have adopted informally: bringing headphones and a comfort playlist to treatment sessions.

Patients who have tried multiple sessions frequently report that dissociation becomes less intense and less bothersome over time. Some describe it as mildly pleasant or neutral rather than frightening. Others continue to find it uncomfortable. The severity on the first session is not necessarily a reliable predictor of what subsequent sessions will feel like.

The Two-Hour Monitoring Session

Every Spravato dose is administered at a certified healthcare facility, and patients must stay for at least two hours of monitoring afterward. They cannot drive for the rest of the day. This requirement exists because esketamine causes temporary increases in blood pressure along with sedation and dissociation. Data from the clinical development program showed that blood pressure peaks within about forty minutes of dosing and typically returns to pre-dose levels by an hour and a half.⁷

From a patient perspective, the monitoring period is both a logistical burden and, for some, a therapeutic element. A qualitative study of patients undergoing esketamine treatment found that the care environment mattered considerably. Patients highlighted the importance of having consistent, engaged nursing staff, a private space, and flexibility in how the session was structured. Feeling safe and supported during the monitoring window helped patients tolerate the dissociative and sedative effects, and some felt it contributed directly to the treatment’s emotional impact.⁸

On the other hand, the logistical demands are a real barrier. You need someone to drive you home. You need to block out a significant portion of a workday, twice a week during the initial phase. Providers also face challenges: a qualitative analysis of mental health providers’ social media posts found that the most commonly discussed implementation problems included billing and reimbursement issues, staffing constraints, pharmacy procurement, and the physical space needed to monitor patients safely.⁹ These provider-side difficulties can trickle down to patients in the form of limited appointment availability and long wait times to start treatment.

Insurance Approval and Cost

Getting insurance to cover Spravato is one of the most common frustrations patients report. Each treatment session can cost well over a thousand dollars without coverage, and the initial phase requires multiple sessions per week. A study tracking pharmacy claims for esketamine found that among patients who submitted a first claim, only about 35% were approved outright. Roughly 46% were rejected, and another 19% were abandoned before a decision was reached. The most common rejection reasons included the claim not being covered by the plan and prior authorization being required. The good news is that approval rates jumped to about 85% by the second treatment session, suggesting that initial paperwork hurdles, rather than outright coverage denial, account for much of the friction.¹⁰

Prior authorization requirements also vary between health plans, and some plans impose criteria that are stricter than the FDA-approved label. A study examining these differences found that the stringency of prior authorization criteria meaningfully shaped which patients could access esketamine and how long they had to wait.¹¹ If your plan requires you to have failed a higher number of antidepressants than the label specifies, or insists on additional documentation, the delay can be weeks or months. Patients often describe the prior authorization process as demoralizing, especially when they have already spent years cycling through medications that did not work.

Staying Better Over Time

A central question for anyone considering Spravato is whether the gains hold up. The SUSTAIN-3 study, which followed patients over an extended period, found that depression scores improved during the initial induction phase and that improvement was maintained during ongoing treatment. About 46% of participants were in remission at the end of the optimization and maintenance phase.¹²

The relapse-prevention data is where Spravato’s value becomes clearest. In a randomized trial comparing continued esketamine-plus-antidepressant treatment against switching to antidepressant-plus-placebo, patients who stayed on esketamine had substantially lower relapse rates. Among those who had achieved stable remission, about 27% relapsed on esketamine compared to 45% on placebo. Among those who had responded but not fully remitted, the gap was even wider: roughly 26% versus 58%. Continued esketamine treatment cut relapse risk by about half in the remission group and by 70% in the response group.¹³ For patients who have achieved a good response, stopping Spravato is not a straightforward decision.

Reassuringly, studies have not found evidence that long-term use leads to withdrawal syndrome. An analysis of patients treated for up to a year showed no consistent pattern of withdrawal symptoms after discontinuation.¹⁴ The concern with stopping is relapse of depression, not physical dependence on the drug. Regarding urological safety, which is a known issue with recreational ketamine use, pharmacovigilance data suggest that prescribed esketamine carries lower or comparable risks of kidney and urinary problems compared to ketamine, likely because the doses and frequency are far below those seen in abuse settings.¹⁵

Effects on Thinking and Memory

Patients understandably worry about whether a drug related to ketamine could dull their cognition over time. The evidence so far is reassuring. A pooled analysis of cognitive data from the four phase 3 clinical trials that supported Spravato’s approval found no worsening of attention, memory, learning, or executive function, whether patients received short-term or long-term treatment.¹⁶

In fact, some patients see cognitive improvement. A preliminary study tracking cognitive function over six months of esketamine treatment found gains in attention, memory, and aspects of executive function. Most improvements appeared within the first three months, though some, like working memory and mental flexibility, continued to improve through month six. These cognitive gains correlated with improvement in depression severity, which makes sense: severe depression itself impairs concentration, memory, and decision-making, so treating the depression can restore cognitive abilities that were dampened by the illness.¹⁷

Functioning Beyond the Mood Score

Feeling less depressed on a rating scale is one thing. Being able to go back to work, maintain relationships, and handle daily tasks is another, and that distinction matters to patients. Research on functional recovery with esketamine has been mixed historically, with a systematic review noting that most early studies did not even measure functional outcomes as a primary goal.¹⁸

More recent head-to-head data tells a more encouraging story. In a 32-week trial comparing esketamine to quetiapine extended release (a commonly used augmentation strategy for treatment-resistant depression), patients on esketamine experienced about 43% more weeks in functional remission. They also had a meaningful reduction in overall work productivity loss compared to the quetiapine group.¹⁹ A systematic review of these comparisons concluded that esketamine showed superior efficacy over quetiapine for clinical response, remission, and functional improvement at both eight and thirty-two weeks.²⁰ For patients weighing Spravato against adding quetiapine to their antidepressant, the functional data tilts the comparison in esketamine’s favor.

When Suicidal Thoughts Are Part of the Picture

Spravato has a separate FDA indication for major depressive disorder with acute suicidal ideation or behavior, and the patient experience in that context has its own character. Pooled data from the ASPIRE trials showed that esketamine plus standard of care produced significantly greater improvement in depression scores compared to placebo plus standard of care as early as four hours after dosing. That advantage persisted at twenty-four hours and was still present at day twenty-five.²¹

Case reports describe rapid resolution of suicidal ideation following esketamine administration, sometimes within the first session, in patients presenting with psychiatric emergencies.²² For patients and their families, the idea that there is a treatment that can meaningfully reduce suicidal thoughts within hours rather than weeks represents a genuinely different kind of option. The emotional weight of that cannot be overstated, even if the clinical trials’ primary endpoints technically measured depression scores rather than suicidality itself.

Spravato in Older Adults

The original clinical trials enrolled relatively few older adults, so whether the treatment works as well and is as tolerable in that population was an open question. A post-hoc analysis from the REAL-ESK study group looked at 30 older adults with treatment-resistant depression and found significant improvement in both depression and anxiety scores. About 53% met criteria for response, and a third achieved remission. The side-effect profile was somewhat different from what younger patients experience: dizziness was the most common complaint at 50%, followed by dissociation at 33%, sedation at 30%, and high blood pressure at about 13%. One in five patients discontinued treatment, a higher dropout rate than is typical in younger cohorts.²³ The blood pressure effects deserve extra attention in older patients, many of whom already have cardiovascular conditions that make transient spikes more concerning.

How Spravato Compares to IV Ketamine

Patients who research Spravato inevitably encounter IV ketamine clinics, which have proliferated in many cities and offer off-label ketamine infusions for depression. A natural question is whether one works better than the other. A recent systematic review and meta-analysis pooling data from multiple head-to-head studies found no statistically significant difference between IV ketamine and intranasal esketamine for either response or remission rates. IV ketamine showed a modest, non-significant trend toward faster onset in some studies, but the overall outcomes were similar.²⁴

The practical differences between the two are substantial, though. Spravato is FDA-approved with a defined safety monitoring protocol, which means it is more likely to be covered by insurance, even if getting that coverage approved is a hassle. IV ketamine clinics typically operate on a cash-pay basis, with individual infusions costing several hundred dollars. IV ketamine also requires an IV line and medical monitoring of its own, but the regulatory framework around it is less standardized. For patients deciding between the two, the choice often comes down to insurance coverage, clinic availability, and personal preference for the treatment setting rather than a clear efficacy advantage of one over the other.